News
We're pleased to recommend linzagolix as a new treatment option for endometriosis. As a once-daily tablet taken at home, it offers a convenient way for people with endometriosis to manage their ...
An artificial intelligence system for potential skin cancer has been conditionally recommended for use in the NHS for the next three years while further evidence is collected. The technology aims to ...
Personalised home hazard assessments and interventions will help to prevent older and at-risk people from suffering from falls, according to new NICE guideline ...
Suggested remit: To appraise the clinical and cost effectiveness of tolebrutinib within its marketing authorisation for treating non-relapsing secondary progressive multiple sclerosis.
Reason for decision Anticipate the topic will be of importance to patients, carers, professionals, commissioners and the health of the public to ensure clinical benefit is realised, inequalities in ...
Reason for decision Anticipate the topic will be of importance to patients, carers, professionals, commissioners and the health of the public to ensure clinical benefit is realised, inequalities in ...
You should read both the consultation document and the accompanying evidence (see the committee papers) before making any comments. You must make your comments ...
Your organisation needs to be registered as a stakeholder before we can accept comments. Not eligible? Contact the stakeholder organisation that most closely represents your interests and pass your ...
Tislelizumab in combination for untreated advanced non-small-cell lung cancer (terminated appraisal)
NICE is unable to make a recommendation about the use in the NHS of tislelizumab (Tevimbra) in combination for untreated advanced non-small-cell lung cancer in adults. This is because BeiGene did not ...
Coding and clinical classification codes for this guidance. This guidance replaces NICE interventional procedures guidance on balloon disimpaction of the baby’s head at emergency caesarean during the ...
There is a simple discount patient access scheme for leniolisib. NHS organisations can get details on the Commercial Access and Pricing (CAP) Portal. Non-NHS organisations can contact ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results